Log in

ASX:ANP - Antisense Therapeutics Stock Price, Forecast & News

Today's Range N/A
50-Day Range
MA: A$0.05
52-Week Range N/A
Volume70,186 shs
Average VolumeN/A
Market Capitalization$21.85 million
P/E RatioN/A
Dividend YieldN/A
Antisense Therapeutics Limited, a biopharmaceutical drug discovery and development company, engages in the research and development of antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 that has completed Phase IIa for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of CD49d for the treatment of inflammation associated with duchenne muscular dystrophy. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Phone61 3 9827 8999



Sales & Book Value

Annual Sales$586,788.00
Book ValueA$0.01 per share



Market Cap$21.85 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ANP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANP and its competitors with MarketBeat's FREE daily newsletter.

Antisense Therapeutics (ASX:ANP) Frequently Asked Questions

What is Antisense Therapeutics' stock symbol?

Antisense Therapeutics trades on the ASX under the ticker symbol "ANP."

How were Antisense Therapeutics' earnings last quarter?

Antisense Therapeutics Limited (ASX:ANP) issued its earnings results on Wednesday, February, 27th. The company reported $0.00 earnings per share for the quarter. View Antisense Therapeutics' Earnings History.

Has Antisense Therapeutics been receiving favorable news coverage?

News headlines about ANP stock have trended negative on Sunday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Antisense Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Antisense Therapeutics.

Who are some of Antisense Therapeutics' key competitors?

What other stocks do shareholders of Antisense Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antisense Therapeutics investors own include Tocagen (TOCA), Miragen Therapeutics (MGEN), Iovance Biotherapeutics (IOVA), Genocea Biosciences (GNCA), Capricor Therapeutics (CAPR) and Applied DNA Sciences (APDN).

Who are Antisense Therapeutics' key executives?

Antisense Therapeutics' management team includes the folowing people:
  • Mr. Mark Diamond, MD & CEO
  • Mr. Phillip Allen Hains, CFO & Company Sec. (Age 60)
  • Dr. George Tachas, Director of Drug Discovery & Patents
  • Susan Turner, Fin. & Admin. Mang.
  • Ms. Nuket Desem, Director of Clinical and Regulatory affairs

How big of a company is Antisense Therapeutics?

Antisense Therapeutics has a market capitalization of $0.00 and generates $586,788.00 in revenue each year. Antisense Therapeutics employs 8 workers across the globe.View Additional Information About Antisense Therapeutics.

What is Antisense Therapeutics' official website?

The official website for Antisense Therapeutics is http://www.antisense.com.au/.

How can I contact Antisense Therapeutics?

The company can be reached via phone at 61 3 9827 8999.

MarketBeat Community Rating for Antisense Therapeutics (ASX ANP)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  15 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  34
MarketBeat's community ratings are surveys of what our community members think about Antisense Therapeutics and other stocks. Vote "Outperform" if you believe ANP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel